Novo Nordisk A/S
Budget
€2 — €0
EP Access
2
accredited persons
Staff
16
3.55 FTE
EU Grants
None
Mission & Goals
Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to serious chronic diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure the diseases we treat. We employ more than 60,000 people in 80 countries, and market our products in 170 countries. In 2023, we served more than 40 million patients worldwide. In 2023, we served more than 6 million patients in the EU. More than 30,000 of our employees are based in the EU. Novo Nordisk is committed to developing its business towards environmental, social and financial sustainability (the triple bottom line).The controlling stake in Novo Nordisk is owned by the Novo Nordisk Foundation. This is a non-profit institution, whose formal purpose is to provide a stable basis for its companies’ operations and to make contributions to scientific, humanitarian and social progress.
EU Legislative Interests
EU pharmaceutical-related policy, as well as broader health, environmental and business-related policy.
Communication Activities
The LinkedIn account of our CEO, Mike Maziar Doustdar, may sometimes include content relevant to activities covered by the Register. Other executive communications sometimes also reference EU policy.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Novo Nordisk is a member of: - EFPIA - The Danish Chamber of Commerce - The Confederation of Danish Industries - EUCOPE - Science|Business
Organisation Members
n/a
Commissioner Meetings
No recorded meetings with EU commissioners.